LXRX
insider transactionsLEXICON PHARMACEUTICALS, INC. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Director
$0
89.3K sh
Own New
-
Exercise·M
Director
$0
89.3K sh
Own +105%
-
Exercise·M
Director
$0
89.3K sh
Own New
-
Exercise·M
Director
$0
89.3K sh
Own +243%
-
Exercise·M
Director
$0
89.3K sh
Own New
-
Exercise·M
Director
$0
89.3K sh
Own +44%
-
Exercise·M
Director
$0
89.3K sh
Own New
-
Exercise·M
Director
$0
89.3K sh
Own +5%
-
Exercise·M
Director
$0
89.3K sh
Own New
-
Exercise·M
Director
$0
89.3K sh
Own New
-
Exercise·M
Director
$0
89.3K sh
Own New
-
Exercise·M
Director
$0
89.3K sh
Own +72%
-
Exercise·M
Director
$0
89.3K sh
Own New
-
Exercise·M
Director
$0
89.3K sh
Own +31%
-
Grant·A
Director
$0
43.5K sh
Own New
-
Grant·A
Director
$0
35.7K sh
Own New
-
Grant·A
Director
$0
43.5K sh
Own New
-
Grant·A
Director
$0
35.7K sh
Own New
-
Grant·A
Director
$0
43.5K sh
Own New
-
Grant·A
Director
$0
35.7K sh
Own New
-
Grant·A
Director
$0
43.5K sh
Own New
-
Grant·A
Director
$0
35.7K sh
Own New
-
Grant·A
Director
$0
43.5K sh
Own New
-
Grant·A
Director
$0
35.7K sh
Own New
-
Grant·A
Director
$0
43.5K sh
Own New
-
Grant·A
Director
$0
35.7K sh
Own New
-
Grant·A
Director
$0
43.5K sh
Own New
-
Grant·A
Director
$0
35.7K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 3, 2026 | Judith L Swain | Exercise M | 89.3K | $0 |
| Jun 3, 2026 | Judith L Swain | Exercise M | 89.3K | $0 |
| Jun 3, 2026 | Diane E. Sullivan | Exercise M | 89.3K | $0 |
| Jun 3, 2026 | Diane E. Sullivan | Exercise M | 89.3K | $0 |
| Jun 3, 2026 | Christopher J Sobecki | Exercise M | 89.3K | $0 |
| Jun 3, 2026 | Christopher J Sobecki | Exercise M | 89.3K | $0 |
| Jun 3, 2026 | Raymond Debbane | Exercise M | 89.3K | $0 |
| Jun 3, 2026 | Raymond Debbane | Exercise M | 89.3K | $0 |
| Jun 3, 2026 | Ivan Cheung | Exercise M | 89.3K | $0 |
| Jun 3, 2026 | Ivan Cheung | Exercise M | 89.3K | $0 |
| Jun 3, 2026 | Sam L Barker | Exercise M | 89.3K | $0 |
| Jun 3, 2026 | Sam L Barker | Exercise M | 89.3K | $0 |
| Jun 3, 2026 | Amouyal Philippe | Exercise M | 89.3K | $0 |
| Jun 3, 2026 | Amouyal Philippe | Exercise M | 89.3K | $0 |
| May 1, 2026 | Christopher J Sobecki | Grant A | 43.5K | $0 |
| May 1, 2026 | Christopher J Sobecki | Grant A | 35.7K | $0 |
| May 1, 2026 | Judith L Swain | Grant A | 43.5K | $0 |
| May 1, 2026 | Judith L Swain | Grant A | 35.7K | $0 |
| May 1, 2026 | Diane E. Sullivan | Grant A | 43.5K | $0 |
| May 1, 2026 | Diane E. Sullivan | Grant A | 35.7K | $0 |
| May 1, 2026 | Raymond Debbane | Grant A | 43.5K | $0 |
| May 1, 2026 | Raymond Debbane | Grant A | 35.7K | $0 |
| May 1, 2026 | Ivan Cheung | Grant A | 43.5K | $0 |
| May 1, 2026 | Ivan Cheung | Grant A | 35.7K | $0 |
| May 1, 2026 | Sam L Barker | Grant A | 43.5K | $0 |
| May 1, 2026 | Sam L Barker | Grant A | 35.7K | $0 |
| May 1, 2026 | Amouyal Philippe | Grant A | 43.5K | $0 |
| May 1, 2026 | Amouyal Philippe | Grant A | 35.7K | $0 |
About LXRX insider trading
This page tracks insider transactions for LEXICON PHARMACEUTICALS, INC. (LXRX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.